---
schema_version: "secwatch.filing_event.v1"
accession: "0002023658-25-000107"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:42:14.016502+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bicara Therapeutics reports Q3 net loss of $36.3M, gets FDA Breakthrough Therapy Designation for ficerafusp alfa

## Summary
- Net loss $36.3M in Q3 2025 vs $17.5M in Q3 2024; R&D expenses rose to $33.0M from $15.9M.
- Cash, equivalents, investments $407.6M as of Sept 30, 2025; expected to fund operations into H1 2029.
- FDA granted Breakthrough Therapy Designation for ficerafusp alfa + pembrolizumab in 1L HPV-negative R/M HNSCC.
- Phase 1b data for 750mg weekly dose of ficerafusp alfa + pembrolizumab expected at ESMO Asia 2025.
- Expanded management team: Jenna Cohen (Chief Corp Affairs), Tanya Green (Chief Dev Officer), Bill Schelman (VP).

## SEC filing metadata
- accession: 0002023658-25-000107
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000202365825000107/0002023658-25-000107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000202365825000107/bcax-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002023658-25-000107
- JSON: https://secwatch.observer/filing/0002023658-25-000107.json
- Plain text: https://secwatch.observer/filing/0002023658-25-000107.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.